Goldman Sachs
MLYS icon

Goldman Sachs’s Mineralys Therapeutics MLYS Stock Holding History

Goldman Sachs’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4M Buy
1,458,676
+673,633
+86% +$18.5M ﹤0.01% 2013
2026
Q1 		$21.3M Sell
785,043
-665,890
-46% -$19.5M ﹤0.01% 2375
2025
Q4 		$52.7M Buy
1,450,933
+739,272
+104% +$29.6M 0.01% 1472
2025
Q3 		$27M Buy
711,661
+84,874
+14% +$1.84M ﹤0.01% 1963
2025
Q2 		$8.48M Buy
626,787
+328,392
+110% +$4.76M ﹤0.01% 2905
2025
Q1 		$4.74M Buy
298,395
+186,480
+167% +$2.14M ﹤0.01% 3412
2024
Q4 		$1.38M Buy
111,915
+22,464
+25% +$294K ﹤0.01% 4589
2024
Q3 		$1.08M Buy
89,451
+32,628
+57% +$395K ﹤0.01% 4580
2024
Q2 		$665K Buy
56,823
+7,532
+15% +$94.9K ﹤0.01% 4670
2024
Q1 		$636K Buy
49,291
+3,706
+8% +$45.8K ﹤0.01% 4615
2023
Q4 		$392K Buy
+45,585
New +$358K ﹤0.01% 4873
2023
Q3 		– Sell
-16,326
Closed -$278K – 5737
2023
Q2 		$278K Sell
16,326
-11,439
-41% -$171K ﹤0.01% 5049
2023
Q1 		$435K Buy
+27,765
New +$467K ﹤0.01% 4900

Other funds holding MLYS

Catalys Pacific
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Samsara BioCapital
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Laurion Capital Management
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs's MLYS Position: Q2 2026 in Review

Goldman Sachs increased its Mineralys Therapeutics (MLYS) stake by 86% in Q2 2026, buying an estimated $18.5M and bringing the position to 1,458,676 shares worth $39.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Goldman Sachs first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $52.7M in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Goldman Sachs held 1,458,676 shares of Mineralys Therapeutics worth $39.4M as of Q2 2026.
  • Goldman Sachs bought 673,633 Mineralys Therapeutics shares in Q2 2026, an estimated $18.5M.
  • Mineralys Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2013 holding.
  • Goldman Sachs first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Goldman Sachs's Mineralys Therapeutics position peaked at $52.7M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.